Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy

Clinical Cancer Research

Volumn 18, Issue 11, 2012, Pages 3100-3111

  McIntyre, Alan ^a   Patiar, Shalini ^a   Wigfield, Simon ^a   Li, Ji Liang ^a   Ledaki, Ioanna ^a   Turley, Helen ^a,b   Leek, Russell ^a,b   Snell, Cameron ^a,b   Gatter, Kevin ^b   Sly, William S ^c   Vaughan Jones, Richard D ^b   Swietach, Pawel ^b   Harris, Adrian L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBONATE DEHYDRATASE IX; SHORT HAIRPIN RNA;

ACIDITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RESISTANCE; CARBONIC ANHYDRASE IX GENE; COLON CANCER; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GLIOBLASTOMA; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PH MEASUREMENT; PRIORITY JOURNAL; TUMOR GENE; TUMOR GROWTH; TUMOR NECROSIS; TUMOR SPHEROID; TUMOR VASCULARIZATION; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; HCT116 CELLS; HT29 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; MICE; NECROSIS; NEOPLASM TRANSPLANTATION; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84861762712     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1877     Document Type: Article

References (50)

1. Raghunand N, Gatenby RA, Gillies RJ. Microenvironmental and cellular consequences of altered blood flow in tumours. Br J Radiol 2003;76 Spec No 1:S11-22. (Pubitemid 39530312)
2. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9. (Pubitemid 39472955)
3. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006;441:437-43. (Pubitemid 44050138)
4. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxiainducible factor 1. Annu Rev Cell Dev Biol 1999;15:551-78. (Pubitemid 32250386)
5. Wykoff CC, Pugh CW, Harris AL, Maxwell PH, Ratcliffe PJ. The HIF pathway: implications for patterns of gene expression in cancer. Novartis Found Symp 2001;240:212-25; discussion 225-31.
6. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000;60:7075-83. (Pubitemid 32059187)
7. Beasley NJ, Wykoff CC, Watson PH, Leek R, Turley H, Gatter K, et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 2001;61: 5262-7. (Pubitemid 32681562)
8. Olive PL, Aquino-Parsons C, MacPhail SH, Liao SY, Raleigh JA, Lerman MI, et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 2001;61: 8924-9. (Pubitemid 34013910)
9. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001;61:6394-9. (Pubitemid 32783244)
10. Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002;8:2595-604. (Pubitemid 34856346)
11. Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 2003;21:473-82. (Pubitemid 46613490)
12. Kaluz S, Kaluzova M, Liao SY, Lerman M, Stanbridge EJ. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta 2009;1795:162-72.
13. Swietach P, Wigfield S, Supuran CT, Harris AL, Vaughan-Jones RD. Cancer-associated, hypoxia-inducible carbonic anhydrase IX facilitates CO2 diffusion. BJU Int 2008;101 Suppl 4:22-4.
14. Swietach P, Wigfield S, Cobden P, Supuran CT, Harris AL, Vaughan- Jones RD. Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J Biol Chem 2008;283:20473-83.
15. Swietach P, Patiar S, Supuran CT, Harris AL, Vaughan-Jones RD. The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths. J Biol Chem 2009; 284:20299-310.
16. Pastorekova S, Parkkila S, Parkkila AK, Opavsky R, Zelnik V, Saarnio J, et al. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997;112:398-408. (Pubitemid 27078826)
17. Liao SY, Rodgers WH, Kauderer J, Bonfiglio TA, Walker JL, Darcy KM, et al. Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States. Int J Cancer 2009;125: 2434-40.
18. Gut MO, Parkkila S, Vernerova Z, Rohde E, Zavada J, Hocker M, et al. Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology 2002;123:1889-903. (Pubitemid 35408313)
19. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 2001;19:3660-8. (Pubitemid 32786278)
20. Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001; 61:7992-8. (Pubitemid 33049392)
21. Watson PH, Chia SK, Wykoff CC, Han C, Leek RD, Sly WS, et al. Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma. Br J Cancer 2003;88:1065-70. (Pubitemid 36560777)
22. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309. (Pubitemid 41443415)
23. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40. (Pubitemid 43108832)
24. Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 2007;67:11244-53. (Pubitemid 350248550)
25. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
26. Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009;15:5020-5.
27. Hong YS, Cho HJ, Kim SY, Jung KH, Park JW, Choi HS, et al. Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer 2009;9:246.
28. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE II, McLendon RE, Desjardins A, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008;26:271-8.
29. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 2009;101:1986-94.
30. Chiche J, Ilc K, Laferriere J, Trottier E, Dayan F, Mazure NM, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 2009;69:358-68.
31. Lou Y, McDonald PC, Oloumi A, Chia SK, Ostlund C, Ahmadi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011;71:3364-76.
32. Ivascu A, Kubbies M. Rapid generation of single-tumor spheroids for high-throughput cell function and toxicity analysis. J Biomol Screen 2006;11:922-32. (Pubitemid 44847146)
33. Harrington LS, Sainson RC, Williams CK, Taylor JM, Shi W, Li JL, et al. Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc Res 2008;75: 144-54. (Pubitemid 351249857)
34. Wykoff CC, Beasley N, Watson PH, Campo L, Chia SK, English R, et al. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol 2001;158:1011-9. (Pubitemid 32221793)
35. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 2001;23:291-9. (Pubitemid 32762920)
36. Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561-73.
37. Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 2007;26:299-310. (Pubitemid 47101667)
38. Swietach P, Hulikova A, Vaughan-Jones RD, Harris AL. New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene 2010;29;6509-21.
39. Svastova E, Zilka N, Zat'ovicova M, Gibadulinova A, Ciampor F, Pastorek J, et al. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp Cell Res 2003;290:332-45. (Pubitemid 37272176)
40. Dorai T, Sawczuk IS, Pastorek J, Wiernik PH, Dutcher JP. The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer 2005;41:2935-47. (Pubitemid 41713134)
41. Griffiths JR. Are cancer cells acidic? Br J Cancer 1991;64:425-7.
42. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res 2006;66:5216-23. (Pubitemid 43844945)
43. Alterio V, Hilvo M, Di Fiore A, Supuran CT, Pan P, Parkkila S, et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci U S A 2009;106:16233-8.
44. Leek RD, Landers RJ, Harris AL, Lewis CE. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 1999;79:991-5. (Pubitemid 29082138)
45. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-6. (Pubitemid 43121975)
46. Pollheimer MJ, Kornprat P, Lindtner RA, Harbaum L, Schlemmer A, Rehak P, et al. Tumor necrosis is a new promising prognostic factor in colorectal cancer. Hum Pathol 2010;41:1749-57.
47. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-22. (Pubitemid 30054364)
48. Zavada J, Zavadova Z, Zat'ovicova M, Hyrsl L, Kawaciuk I. Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br J Cancer 2003;89:1067-71. (Pubitemid 37239213)
49. Davis ID, Wiseman GA, Lee FT, Gansen DN, Hopkins W, Papenfuss AT, et al. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun 2007;7:13.
50. Guzel O, Maresca A, Scozzafava A, Salman A, Balaban AT, Supuran CT. Carbonic anhydrase inhibitors. Synthesis of 2,4,6-trimethylpyridinium derivatives of 2-(hydrazinocarbonyl)-3-aryl-1H-indole-5-sulfonamides acting as potent inhibitors of the tumor-associated isoform IX and XII. Bioorg Med Chem Lett 2009;19:2931-4.